Decatur Memorial Hospital
- Type
- Teaching hospital
- Where
- Decatur, IL
- Medicare CCN
- 140135
- Received
- $289,319 in 87 records, 2020 ($3,776 general, $285,542 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: DECATUR MEMORIAL HOSPITAL Fuzzy (name and state)
- Federal award recipient: DECATUR MEMORIAL HOSPITAL Fuzzy (name and state)
- Nonprofit: DECATUR MEMORIAL HOSPITAL Fuzzy (name and state)
- Trademark owner: Decatur Memorial Hospital Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 3 | $3,776 |
| 2020 | Research payment | 84 | $285,542 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | 3 | $92,152 | 2020 |
| Merck Sharp & Dohme LLC | 66 | $85,056 | 2020 |
| SEAGEN INC. | 4 | $41,040 | 2020 |
| Boehringer Ingelheim Pharma GmbH & Co.KG | 1 | $30,565 | 2020 |
| AstraZeneca UK Limited | 2 | $14,159 | 2020 |
| PUMA BIOTECHNOLOGY, INC. | 1 | $10,000 | 2020 |
| Incyte Corporation | 2 | $6,569 | 2020 |
| Cook Incorporated | 2 | $3,412 | 2020 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $3,000 | 2020 |
| Radius Health, Inc. | 2 | $1,500 | 2020 |
| EMD Serono, Inc. | 1 | $750 | 2020 |
| SANOFI US SERVICES INC. | 1 | $750 | 2020 |
| Linvatec Corporation | 1 | $364 | 2020 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 84 | $285,542 |
| Charitable Contribution | 2 | $3,412 |
| Grant | 1 | $364 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | AstraZeneca UK Limited | $1,159 | Research payment | In-kind items and services | An Open-label, Multi-drug, Multi-center Phase II Combination Study of AZD4635 in Patients with Prostate Cancer | 2020 | |
| 2020-12-31 | Linvatec Corporation | $364 | Grant | In-kind items and services | SHOULDER MANUAL INSTRUMENTS Device, ORTHOPEDIC SURGERY | 2020 | |
| 2020-12-29 | Merck Sharp & Dohme LLC | $41 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-12-23 | SEAGEN INC. | $14,095 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2020 |
| 2020-12-17 | Merck Sharp & Dohme LLC | $19,541 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine,Cisplatin versus Placebo Plus Gemcitabine,Cis | 2020 |
| 2020-12-14 | Merck Sharp & Dohme LLC | $60 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-12-14 | Merck Sharp & Dohme LLC | $30 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-12-01 | AstraZeneca UK Limited | $13,000 | Research payment | Cash or cash equivalent | An Open-label, Multi-drug, Multi-center Phase II Combination Study of AZD4635 in Patients with Prostate Cancer | 2020 | |
| 2020-12-01 | EMD Serono, Inc. | $750 | Research payment | Cash or cash equivalent | M7824 (PD-L1 TRAP) | An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (bintrafusp alfa) versus Pembroliz | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $50 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $50 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $50 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $50 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $50 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $50 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-06 | Merck Sharp & Dohme LLC | $6,312 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine,Cisplatin versus Placebo Plus Gemcitabine,Cis | 2020 |
| 2020-11-03 | SEAGEN INC. | $25,573 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2020 |
| 2020-11-02 | Merck Sharp & Dohme LLC | $60 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-02 | Merck Sharp & Dohme LLC | $30 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-10-20 | Merck Sharp & Dohme LLC | $41 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-10-12 | Merck Sharp & Dohme LLC | $60 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-10-12 | Merck Sharp & Dohme LLC | $30 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-10-07 | Cook Incorporated | $1,882 | Charitable Contribution | In-kind items and services | NOT APPLICABLE Device, VASCULAR ACCESS | 2020 | |
| 2020-10-07 | Cook Incorporated | $1,530 | Charitable Contribution | In-kind items and services | C-(U)TLM Device, CENTRAL VENOUS CATHETERS | 2020 | |
| 2020-09-25 | Merck Sharp & Dohme LLC | $6,194 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine,Cisplatin versus Placebo Plus Gemcitabine,Cis | 2020 |
| 2020-09-22 | Merck Sharp & Dohme LLC | $564 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine,Cisplatin versus Placebo Plus Gemcitabine,Cis | 2020 |
| 2020-09-15 | Merck Sharp & Dohme LLC | $60 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-09-15 | Merck Sharp & Dohme LLC | $30 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-09-01 | Radius Health, Inc. | $600 | Research payment | Cash or cash equivalent | A RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF ELACESTRANT (RAD1901) VERSUS INVESTIGATORS CHOICE OF FULVESTRANT OR AROMATAS | 2020 | |
| 2020-09-01 | Merck Sharp & Dohme LLC | $60 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-09-01 | Merck Sharp & Dohme LLC | $30 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-08-31 | Merck Sharp & Dohme LLC | $185 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine,Cisplatin versus Placebo Plus Gemcitabine,Cis | 2020 |
| 2020-08-31 | Merck Sharp & Dohme LLC | $93 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine,Cisplatin versus Placebo Plus Gemcitabine,Cis | 2020 |
| 2020-08-26 | Merck Sharp & Dohme LLC | $5,074 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine,Cisplatin versus Placebo Plus Gemcitabine,Cis | 2020 |
| 2020-08-26 | Merck Sharp & Dohme LLC | $900 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine,Cisplatin versus Placebo Plus Gemcitabine,Cis | 2020 |
| 2020-08-26 | SEAGEN INC. | $260 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2020 |
| 2020-08-20 | Merck Sharp & Dohme LLC | $500 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-08-05 | Merck Sharp & Dohme LLC | $60 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-08-05 | Merck Sharp & Dohme LLC | $30 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-07-24 | Merck Sharp & Dohme LLC | $14,299 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine,Cisplatin versus Placebo Plus Gemcitabine,Cis | 2020 |
| 2020-07-16 | Bayer Healthcare Pharmaceuticals Inc. | $3,000 | Research payment | Cash or cash equivalent | Stivarga Drug, Oncology | Clinical Study Site Agreement | 2020 |
| 2020-06-24 | Merck Sharp & Dohme LLC | $600 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine,Cisplatin versus Placebo Plus Gemcitabine,Cis | 2020 |
| 2020-06-23 | AstraZeneca Pharmaceuticals LP | $57,277 | Research payment | Cash or cash equivalent | IMFINZI Drug, Oncology | A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Ste | 2020 |
| 2020-05-28 | SEAGEN INC. | $1,111 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2020 |
| 2020-05-28 | Merck Sharp & Dohme LLC | $60 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-05-28 | Merck Sharp & Dohme LLC | $30 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-05-22 | Merck Sharp & Dohme LLC | $1,343 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine,Cisplatin versus Placebo Plus Gemcitabine,Cis | 2020 |
| 2020-05-18 | Merck Sharp & Dohme LLC | $60 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-05-18 | Merck Sharp & Dohme LLC | $30 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-05-15 | AstraZeneca Pharmaceuticals LP | $3,300 | Research payment | Cash or cash equivalent | A Phase II Study of the Dual Immune Checkpoint Blockade with Durvalumab plus Tremelimumab Following Palliative Hypofract | 2020 | |
| 2020-05-07 | Radius Health, Inc. | $900 | Research payment | Cash or cash equivalent | A RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF ELACESTRANT (RAD1901) VERSUS INVESTIGATORS CHOICE OF FULVESTRANT OR AROMATAS | 2020 | |
| 2020-05-01 | Merck Sharp & Dohme LLC | $19,541 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine,Cisplatin versus Placebo Plus Gemcitabine,Cis | 2020 |
| 2020-04-16 | Merck Sharp & Dohme LLC | $148 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine,Cisplatin versus Placebo Plus Gemcitabine,Cis | 2020 |
| 2020-04-09 | Merck Sharp & Dohme LLC | $60 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-04-09 | Merck Sharp & Dohme LLC | $30 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-04-03 | Merck Sharp & Dohme LLC | $600 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine,Cisplatin versus Placebo Plus Gemcitabine,Cis | 2020 |
| 2020-03-11 | Merck Sharp & Dohme LLC | $500 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-03-04 | Merck Sharp & Dohme LLC | $60 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-03-04 | Merck Sharp & Dohme LLC | $41 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-03-04 | Merck Sharp & Dohme LLC | $30 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-02-26 | Incyte Corporation | $3,500 | Research payment | Cash or cash equivalent | Evaluation Of Ruxolitinib And Azacytidine Combination As A Therapy For Patients With Myelofibrosis And Myelodysplastic S | 2020 | |
| 2020-02-17 | Merck Sharp & Dohme LLC | $60 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-02-17 | Merck Sharp & Dohme LLC | $30 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-02-14 | AstraZeneca Pharmaceuticals LP | $31,575 | Research payment | Cash or cash equivalent | A Phase II Study to Assess the Activity of PD-L1 Inhibition with Durvalumab after Chemo-Radiotherapy in Patients with St | 2020 | |
| 2020-02-11 | Merck Sharp & Dohme LLC | $500 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-01-31 | Boehringer Ingelheim Pharma GmbH & Co.KG | $30,565 | Research payment | In-kind items and services | IIS ONC Study Drug Supply 2020 | 2020 | |
| 2020-01-27 | PUMA BIOTECHNOLOGY, INC. | $10,000 | Research payment | Cash or cash equivalent | NERLYNX Drug, ONCOLOGY | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF NERATINIB (HKI-272) AFTER TRASTUZUMAB IN WOMEN WITH EARLY-STAGE | 2020 |
| 2020-01-27 | Merck Sharp & Dohme LLC | $5,100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine,Cisplatin versus Placebo Plus Gemcitabine,Cis | 2020 |
| 2020-01-22 | Incyte Corporation | $3,069 | Research payment | Cash or cash equivalent | Evaluation Of Ruxolitinib And Azacytidine Combination As A Therapy For Patients With Myelofibrosis And Myelodysplastic S | 2020 | |
| 2020-01-13 | SANOFI US SERVICES INC. | $750 | Research payment | Cash or cash equivalent | SARCLISA Biological, Oncology | A Phase 1b Study of SAR650984 (Anti-CD38 mAb) in Combination with Pomalidomide and Dexamethasone for the Treatment of Re | 2020 |
| 2020-01-08 | Merck Sharp & Dohme LLC | $41 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Decatur, IL, county Macon County, IL, state Illinois; placed by its city name.
| Measure | Place (city or town) Decatur, IL | County Macon County, IL | State Illinois |
|---|---|---|---|
| Population B01003 | 69,815 | 101,849 | 12,694,798 |
| Population, 2020 census P1 | 70,522 | 103,998 | 12,812,508 |
| Median age B01002 | 39.2 | 40.6 | 39.0 |
| Under 18 B01001 | 21.0% | 22.6% | 21.8% |
| 65 and over B01001 | 21.3% | 21.0% | 17.0% |
| Households B11001 | 30,920 | 43,468 | 5,036,449 |
| Foreign born B05002 | 3.1% | 2.7% | 14.7% |
| Median household income B19013 | $51,592 | $62,666 | $83,390 |
| Median family income B19113 | $74,623 | $86,291 | $106,018 |
| Per capita income B19301 | $32,769 | $36,605 | $46,406 |
| Poverty rate B17001 | 19.4% | 15.0% | 11.8% |
| Unemployment rate B23025 | 8.3% | 6.8% | 5.8% |
| Civilian labor force B23025 | 31,960 | 47,235 | 6,652,134 |
| Mean commute (minutes) B08013 | 17.7 | 19.4 | 27.8 |
| Bachelor's degree or higher B15003 | 21.6% | 24.4% | 37.8% |
| Housing units B25001 | 36,018 | 49,630 | 5,457,452 |
| Owner-occupied B25003 | 62.9% | 70.2% | 67.1% |
| Renters B25003 | 37.1% | 29.8% | 32.9% |
| Median home value B25077 | $99,600 | $127,300 | $263,300 |
| Median gross rent B25064 | $845 | $847 | $1,274 |
| White, not Hispanic B03002 | 64.9% | 73.3% | 58.1% |
| Black B03002 | 23.3% | 16.2% | 13.3% |
| Hispanic or Latino B03002 | 3.3% | 2.9% | 18.8% |
| Asian B03002 | 1.5% | 1.5% | 5.9% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Economy now FRED unemployment 4.6% in Sep 2026 (4.5% a year earlier); per capita personal income $78,987 in 2025, up 28% in five years (+3.1% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Decatur, IL.
Comments